Avenda Health’s AI tool, Unfold AI, for mapping prostate cancer, received a Category III CPT code for 2024 from the AMA. The code, X237T, facilitates precise cancer localization and treatment planning through an AI-generated 3D map, enhancing individualized care. Recognized for advancing cancer diagnosis and treatment, Unfold AI’s adoption by Urology Associates in Maryland and its planned national expansion mark significant steps in making cutting-edge cancer care widely accessible.
Avenda Health has achieved a major milestone with its AI-based prostate cancer mapping tool, Unfold AI, receiving a Category III CPT code from the American Medical Association (AMA) for its 2024 CPT code set. This inclusion will enhance accessibility to individualized prostate cancer treatment, streamlining the process of claim submissions and supporting medical research and guidelines development.
The new CPT code, X237T, covers the non-invasive mapping of prostate cancer. It involves analyzing image-guided fusion biopsy and pathology data, visualizing tumor margins, and determining their volume and location, complemented by physician interpretation and reporting.
Dr. Brittany Berry-Pusey, COO and co-founder of Avenda Health, expressed that this achievement reflects their commitment to pioneering cancer care and improving technology availability for patients. Unfold AI serves as a decision support platform, generating a 3D, AI-created map to aid physicians in precisely locating and planning treatment for prostate cancer. This custom map is created by integrating specific patient data, utilizing advanced machine learning techniques.
The tool’s recent implementation by Dr. Matthew Allaway at Urology Associates in Maryland marks its clinical application. Avenda Health is now looking to broaden its reach to major academic hospitals and urology clinics across the country.
The latest Category III codes, including Avenda’s new code, will be available on the AMA CPT website from January 1, 2024, and will become effective on July 1, 2024.
